Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Aug 29, 2022 1:45pm
149 Views
Post# 34927277

RE:RE:Anyone in Bicycle Theraputics

RE:RE:Anyone in Bicycle Theraputics FYI, there are a few other companies pursuing PDCs and a few have been bought up and are in larger firms (The lutathera PDC was bought up by Novartis or someone like that).  THere's one in Japan, two in Europe (one very early startup).  Here's a good piece on the science and some players.   THTX is mentioned in them.

https://pubmed.ncbi.nlm.nih.gov/34641586/

https://pubmed.ncbi.nlm.nih.gov/33346298/



Wino115 wrote: Welcome SS - yes, it's one of the comps for THTX, however a slightly different take on the science. They use peptides, but have a construct that's more complex (the "bi" piece) and they have so far pursued different targets expressed in the specific cancers they are currently trialing.  But the model of proving up your concept and then partnering for either regions you won't be able to access or for indications that aren't "central" to your strategy is certainly one path THTX can take if there is POC with TH1902. 

Bicycle has also received a lot of funding from UK Cancer Research, so you have a tiny bit of similarity in THTX getting research grants (although a lot smaller so far).  

But it's definitely one to comp on.  It is certainly larger market cap, has a number of investment banks involved with research, etc... I guess that shows the power of the more traditional route of raising capital via the banks and having their analysts follow you. Remember, THTX is over 20 years old and isn't a newly funded biotech that gets attention. If you get Proof of Concept (POC), we can assume they will need to raise money for further Phase 2 and 3 trials for at least one cancer and, hopefully, others.  Then it would look a lot like Bicycle Therapeutics.  Other comps are in the ADC area and fairly close in strategy, etc... (SeaGen, Sutro, etc...).  We also closely follow how Trodelvy is developing and Enhertu.  

THTX does have the advantage of getting FDA  fast-track - I'm not sure if Bicycle has that but they might. It should help in moving along the various FDA trial steps toward approval quicker and possibly getting breakthrough designation which would definitely bring huge publicity and attraction to the investment thesis.

SS1316 wrote:

 

 Excuse me for my ignorance I'm relatively new with TH but I was looking for TH's peers in the field of companies developing a PDC that are publicly traded. Seems that BCYC is further along in their development with multiple drugs but they also seem to be more widely known about which is not hard to do. Are we even in the same ball park as BCYC? Could we possibly see more value if BCYC advances their drugs and show success? Just looking for a synopsis from the minds of this board. 





<< Previous
Bullboard Posts
Next >>